HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Online-Only Appendix Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Ashwell, S. G Articles by Home, P. D PubMed PubMed Citation Articles by Ashwell, S. G Articles by Home, P. D Social Bookmarking                What's this?

Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in people with Type 1 diabetes

¹Newcastle University, Newcastle upon Tyne, UK
²Royal Holloway, University of London, London, UK
³sanofi-aventis, Bridgewater, NJ, USA
⁴Health Outcomes Research, Accovion, Frankfurt, Germany

simon.ashwell{at}stees.nhs.uk

ABSTRACT

Objective: To compare quality of life and treatment satisfaction when using insulin glargine + insulin lispro with that on NPH insulin + unmodified human insulin in adults with Type 1 diabetes managed with multiple injection regimens.

Research Design and Methods: As part of a 32-week, five-centre, two-way cross-over study in 56 people with Type 1 diabetes randomized to evening insulin glargine + meal-time insulin lispro or to NPH insulin (once- or twice-daily) + meal-time unmodified human insulin, the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and the Audit of Diabetes Dependent Quality of Life (ADDQoL) questionnaire were completed at baseline, weeks 16 and 32, with additional interim DTSQ measurements.

Results: For all patients combined, mean baseline present quality of life (QoL) score was 1.3, reflecting ‘good’ QoL. Present QoL improved with glargine+lispro but did not change with NPH+human insulin (1.6±0.1 [±SE] vs 1.3±0.1, difference 0.3 (95 % CI 0.1, 0.6), p=0.014). Baseline mean average weighted impact score (AWI) of diabetes on QoL was –1.8, indicating a negative impact of diabetes on QoL. AWI score at endpoint improved significantly with glargine+lispro but changed little with NPH+human insulin (–1.4±0.1 vs –1.7±0.1, 0.3 (0.0, 0.6), p=0.033). Treatment satisfaction (DTSQ 36-0 scale score) at endpoint was markedly greater with glargine+lispro compared with NPH+human insulin (32.2±3.4 vs 23.9±7.2, 8.6 (6.5, 10.6), p<0.001).

Conclusions: Insulin glargine + insulin lispro improves treatment satisfaction, reduces the negative impact of diabetes on QoL and improves QoL, in comparison with NPH insulin + unmodified human insulin in Type 1 diabetes.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?